Evidence map›Paper›PMID 35050996›Full record

SynthesisToxins2021

Use of Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)-(Equine) (BAT

Geraldine S Parrera, Hugo Astacio, Priya Tunga, Deborah M Anderson, Christine L Hall, Jason S Richardson

Registry-linked trialOpen access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Toxins, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02051062 (Pharmacokinetics of Botulism Antitoxin Heptavalent), which is not on this map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02051062 phase4enrolling by invitationnot on this map

Pharmacokinetics of Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine) (BAT®) in Pediatric Patients With a Confirmed or Suspected Exposure to Botulinum Neurotoxin

TypeinterventionalSponsorEmergent BioSolutionsRan2014 to 2028Enrolled10ConditionsBotulismArmsBlood sample collection
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. [Use of vaccines to prevent the development of bacterial resistance].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2026
    Review
  2. Review
  3. Investigating the dual nature ofLe infezioni in medicina · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Geraldine S ParreraPharmacovigilance Department, Emergent BioSolutions Canada Incorporated (Inc.), Winnipeg, MB R3T 5Y3, Canada.ORCID 0000-0002-2612-4031
Hugo AstacioPharmacovigilance Department, Emergent BioSolutions Canada Incorporated (Inc.), Winnipeg, MB R3T 5Y3, Canada.
Priya TungaBiostatistics Department, Emergent BioSolutions Canada Inc., Winnipeg, MB R3T 5Y3, Canada.
Deborah M AndersonBiostatistics Department, Emergent BioSolutions Canada Inc., Winnipeg, MB R3T 5Y3, Canada.
Christine L HallClinical Research Department, Emergent BioSolutions Canada Inc., Winnipeg, MB R3T 5Y3, Canada.
Jason S RichardsonClinical Research Department, Emergent BioSolutions Canada Inc., Winnipeg, MB R3T 5Y3, Canada.
Emergent BioSolutions (Canada) · CA

Funding

Biomedical Advanced Research and Development Authority HHSO100200600017C
6 · The paper itself

Abstract

Botulism is a rare, sometimes fatal paralytic illness caused by botulinum neurotoxins. BAT

Indexed as

Botulinum AntitoxinBotulismHumansBotulinum AntitoxinBAT productbotulismBotulism Antitoxin Heptavalentequine-derivedsafety review

Identifiers

PMID35050996
PMCPMC8778610
OpenAlexW4200014208

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.